We are live on ! Find out more
TG

TRV GP Portfolio holdings

AUM $18.9M
1-Year Est. Return 541.67%
This Fund
S&P 500
This Quarter Est. Return
-17.66%
1 Year Est. Return
+541.67%
3 Year Est. Return
+3,178.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$63.7M
AUM Growth
-$24.6M
Cap. Flow
-$4.54M
Cap. Flow %
-7.13%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

1
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$4.29M
2
LRMR icon
Larimar Therapeutics
LRMR
+$250K

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYTM icon
1
Rhythm Pharmaceuticals
RYTM
$7.28B
$38.5M 60.35%
1,781,437
-200,000
-10% -$4.29M
CNST
2
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$19.6M 30.76%
3,034,083
– –
CARM
3
DELISTED
Carisma Therapeutics
CARM
$5.67M 8.89%
242,080
– –
LRMR icon
4
Larimar Therapeutics
LRMR
$381M
– –
-17,531
Closed -$250K

Similar funds

KA
KSL Advisors Denver, Colorado $16.1M AUM
FRGX
First Reserve GP XII Stamford, Connecticut $3.16M AUM 24.66% 1-Year Est. Return
DHRFI
DCM Hybrid RMB Fund International Menlo Park, California $35.3M AUM
SA
Silversage Advisors Irvine, California $2.41M AUM 46.55% 1-Year Est. Return
YECIP
YT Extraction Co Investment Partners New York $1.73M AUM
FFIM
Founders Fund II Management San Francisco, California $1.32M AUM
ES
Equitec Specialists Chicago, Illinois $708K AUM 25.27% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM

TRV GP's Q3 2019 Portfolio in Review

As of Q3 2019, TRV GP held 4 positions worth $63.7M, down 28% from $88.4M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

TRV GP withdrew a net $4.54M in Q3 2019, closing 1 position and reducing 1 holding. Its most notable exit was Larimar Therapeutics, an estimated $250K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • TRV GP's biggest Q3 2019 reduction was Rhythm Pharmaceuticals, cutting an estimated $4.29M.
  • TRV GP fully exited Larimar Therapeutics in Q3 2019, selling an estimated $250K.
  • TRV GP's ten largest holdings make up 100% of its $63.7M portfolio in Q3 2019.
  • TRV GP opened 0 new positions and closed 1 in Q3 2019.
  • TRV GP's portfolio value fell 28% quarter-over-quarter to $63.7M.

Based on TRV GP's 13F filing for Q3 2019, filed 4 Nov 2019.